Provided by Tiger Trade Technology Pte. Ltd.

Insmed

128.80
+3.913.13%
Pre-market: 128.68-0.1200-0.09%04:13 EDT
Volume:2.84M
Turnover:362.76M
Market Cap:28.13B
PE:-31.51
High:130.83
Open:124.00
Low:121.04
Close:124.89
52wk High:212.75
52wk Low:90.39
Shares:218.38M
Float Shares:216.82M
Volume Ratio:1.63
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0882
EPS(LYR):-6.4200
ROE:-87.22%
ROA:-22.17%
PB:37.13
PE(LYR):-20.06

Loading ...

Insmed Reports Inducement Awards of 115,320 RSUs and Stock Options Priced at USD 121.82 Per Share

Reuters
·
Sep 04

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 04

Is Insmed (INSM) Undervalued Following Japan Approval For BRINSUPRI?

Simply Wall St.
·
Sep 01

Movement Alert|Insmed Rises 5.87% in Pre-Market Trading, Core Drug Brinsupri Approved in Japan

Market Focus
·
Aug 28

RBC Capital Reaffirms Their Buy Rating on Insmed (INSM)

TIPRANKS
·
Aug 27

Insmed to Present at Cantor Fitzgerald Global Healthcare Conference

Reuters
·
Aug 26

U.S. Research Roundup-Masco, Sherwin-Williams, Vulcan Materials

Reuters
·
Aug 25

Insmed Stock Seen by Mizuho as Undervalued

Dow Jones
·
Aug 25

Insmed Earns Buy Rating as Brinsupri Japan Approval Drives Stronger Global Outlook and Price Target Raised to $195

TIPRANKS
·
Aug 25

Mizuho ups Insmed price target, says share weakness is unwarranted

TIPRANKS
·
Aug 25

Insmed's Lung Disease Drug Gets Approved in Japan

MT Newswires Live
·
Aug 24

Insmed Says Japan Health Ministry Approves Brinsupri for Non-Cystic Fibrosis Bronchiectasis

Reuters
·
Aug 24

Brinsupri® (Brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients with Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

THOMSON REUTERS
·
Aug 24

Insmed Director Melvin Sharoky, M.D. Sells 5,000 Shares for $637,650

Reuters
·
Aug 20

Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Insmed (INSM)

TIPRANKS
·
Aug 18

Insmed (INSM) Earnings Narrow Losses As Fair Value Comes Back Into Focus

Simply Wall St.
·
Aug 18

Insmed Extends Its Pulmonary Hypertension Push With Long-Term TPIP Study

TIPRANKS
·
Aug 14

Top Insmed Executive Executes Major Multi-Million Dollar Stock Move

TIPRANKS
·
Aug 13

Insmed COO Roger Adsett Sells 239,850 Shares for $31.97 Million

Reuters
·
Aug 13

Insmed Price Target Raised to $195.00/Share from $185.00 by Truist Securities

Dow Jones
·
Aug 11